View in EDS HTML Full Text PDF Full Text

Zolbetuximab or Immunotherapy as the Initial Targeted Therapy in CLDN18.2-Positive, HER2-Negative Advanced Gastric Cancer: Weighing the Options.

Saved in:
Bibliographic Details
Title: Zolbetuximab or Immunotherapy as the Initial Targeted Therapy in CLDN18.2-Positive, HER2-Negative Advanced Gastric Cancer: Weighing the Options.
Authors: Easaw, Jacob C.1 (AUTHOR) jay.easaw@albertahealthservices.ca, Lim, Howard J.2 (AUTHOR), Karachiwala, Hatim3 (AUTHOR), Gill, Sharlene2,4 (AUTHOR), Zhu, Xiaofu1 (AUTHOR), Bateman, Justin4 (AUTHOR)
Source: Current Oncology. Nov2025, Vol. 32 Issue 11, p648. 12p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:11980052
DOI:10.3390/curroncol32110648